EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making

Lan Zhong, Liang Song

Frontiers in Pharmacology · 09.11.2026 · 17

DOI: 10.3389/fphar.2026.1931140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.11.2026. Verfasst von Lan Zhong und 1 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bevacizumab is an important component of first-line therapy for advanced epithelial ovarian cancer; however, the precise identification of patients who will benefit and how to optimize its use in the era of poly (ADP-ribose) polymerase inhibitors (PARPi) remains a core challenge in clinical practice. This review systematically revisits the pivotal phase III trials GOG-0218 and ICON7, together with their inherent limitations, with a particular focus on the role of KELIM score as a dynamic marker of chemotherapy sensitivity in predicting bevacizumab efficacy. Based on the interaction test from GOG-0218, the available evidence suggests that BRCA/homologous recombination deficiency (HRD) status does not alter the single-agent activity of bevacizumab; however, these genetic markers remain crucial for guiding PARPi or combination regimens. A key clinical dilemma arises when patients with a BRCA mutation have already received bevacizumab during first-line chemotherapy: should bevacizumab be continued or discontinued during the maintenance phase? This review presents a preference analysis and individualized decision-making factors based on available indirect evidence and current guidelines. Finally, a clinical decision pathway that integrates KELIM assessment with HRD testing is proposed to provide an evidence-based reference framework for the rational use of bevacizumab in first-line advanced ovarian cancer.

Zitieren

APA

Zhong, L., & Song, L. (2026). Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1931140

Vancouver

Zhong L, Song L. Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1931140

BibTeX
@article{Zhong2026,
  author = {Zhong, Lan and Song, Liang},
  title = {Bevacizumab in first-line postoperative treatment of advanced ovarian cancer: from high-risk stratification to precision decision-making},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1931140}
}
Kostenlos starten →